Amneal Pharmaceuticals will present at two investor conferences in June 2025, featuring key executives and live webcasts.
Quiver AI Summary
Amneal Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference on June 5, 2025, at 9:20 AM ET, and the Goldman Sachs Global Healthcare Conference on June 10, 2025, at 10:40 AM ET. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company at both events. A live webcast of the presentations will be available on the company's investor website, with replays provided afterward. Amneal, based in Bridgewater, NJ, is a global biopharmaceutical company focused on developing, manufacturing, and distributing a wide range of pharmaceuticals, including injectables and biosimilars, and has a growing portfolio of branded products for central nervous system and endocrine disorders.
Potential Positives
- Amneal Pharmaceuticals' participation in prestigious investor conferences highlights its commitment to transparency and communication with investors.
- The inclusion of top executives Chirag Patel and Tasos Konidaris in the conferences signals strong leadership and confidence in the company's direction.
- The live webcast and availability of replays increase accessibility for potential investors and stakeholders, enhancing engagement opportunities.
Potential Negatives
- None
FAQ
What are the upcoming investor conferences for Amneal Pharmaceuticals?
Amneal Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5, 2025, and Goldman Sachs Global Healthcare Conference on June 10, 2025.
Who will represent Amneal Pharmaceuticals at the conferences?
Chirag Patel, Co-CEO and President, and Tasos Konidaris, CFO, will represent Amneal at both conferences.
When is Amneal's presentation scheduled at the Jefferies conference?
The presentation at the Jefferies Global Healthcare Conference is scheduled for June 5, 2025, at 9:20 AM ET.
How can I access the live webcast of the conferences?
A live webcast of the conferences will be available at https://investors.amneal.com with replays following both events.
What is the focus of Amneal Pharmaceuticals' product portfolio?
Amneal Pharmaceuticals focuses on a diverse portfolio of over 280 products, including injectables, biosimilars, and branded pharmaceuticals for CNS and endocrine disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRX Insider Trading Activity
$AMRX insiders have traded $AMRX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:
- TUSHAR BHIKHUBHAI PATEL sold 5,000,000 shares for an estimated $41,750,000
- GAUTAM PATEL has made 0 purchases and 7 sales selling 328,668 shares for an estimated $2,737,344.
- ANDREW S BOYER (Executive Vice President) sold 125,000 shares for an estimated $1,111,250
- TASOS KONIDARIS (Executive Vice President & CFO) sold 100,000 shares for an estimated $891,000
- JASON B. DALY (EVP, Chief Legal Officer) has made 0 purchases and 2 sales selling 90,000 shares for an estimated $792,159.
- EMILY PETERSON ALVA sold 80,000 shares for an estimated $712,000
- JOHN KIELY sold 50,000 shares for an estimated $379,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AMRX Hedge Fund Activity
We have seen 141 institutional investors add shares of $AMRX stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FOSUN INTERNATIONAL LTD removed 1,720,855 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $13,629,171
- CITADEL ADVISORS LLC removed 1,488,939 shares (-16.6%) from their portfolio in Q1 2025, for an estimated $12,477,308
- PHOCAS FINANCIAL CORP. added 1,057,489 shares (+523.8%) to their portfolio in Q1 2025, for an estimated $8,861,757
- WOODLINE PARTNERS LP added 937,035 shares (+165.2%) to their portfolio in Q1 2025, for an estimated $7,852,353
- VANGUARD GROUP INC added 920,758 shares (+6.2%) to their portfolio in Q1 2025, for an estimated $7,715,952
- ACADIAN ASSET MANAGEMENT LLC added 880,471 shares (+51.3%) to their portfolio in Q1 2025, for an estimated $7,378,346
- MILLENNIUM MANAGEMENT LLC added 762,842 shares (+57.6%) to their portfolio in Q1 2025, for an estimated $6,392,615
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit
www.amneal.com
and follow us on
LinkedIn
.
Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]
